Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
1.655
+0.105 (6.62%)
Nov 21, 2024, 1:17 PM EST - Market open
Entera Bio Employees
As of December 31, 2023, Entera Bio had 18 total employees, including 17 full-time and 1 part-time employees. The number of employees increased by 1 or 5.88% compared to the previous year.
Employees
18
Change (1Y)
1
Growth (1Y)
5.88%
Revenue / Employee
$5,500
Profits / Employee
-$509,889
Market Cap
60.96M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| bluebird bio | 375 |
| InterCure | 270 |
| Atara Biotherapeutics | 225 |
| Hyperfine | 131 |
| X4 Pharmaceuticals | 93 |
| Spero Therapeutics | 46 |
| enVVeno Medical | 31 |
| Aileron Therapeutics | 15 |
ENTX News
- 12 days ago - Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders - GlobeNewsWire
- 3 months ago - Entera Bio to Participate in Upcoming Investor and Scientific Conferences - GlobeNewsWire
- 3 months ago - Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 months ago - Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member - GlobeNewsWire
- 6 months ago - Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024 - GlobeNewsWire
- 6 months ago - Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 8 months ago - Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research - GlobeNewsWire